Research Impact

h-index

N/A

Research impact score

Publications

Total publications

Trial Results

Published trial results

Citations

Total citations

Drug Portfolio

DRUG(11)

Etrasimod

7 trials

phase_2phase_3

arena-pharmaceuticals

Olorinab

3 trials

phase_1phase_2

arena-pharmaceuticals

APD125

1 trial

phase_2

arena-pharmaceuticals

3 unique interventions1 categories

Analytics

Trial Phases

Phase 11

Phase 28

Phase 32

Trial Status

Completed7

Terminated4

Role Distribution

Other Roles11

Activity Timeline

Clinical Trials (11)

NCT04655599Phase 1Terminated

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

StudydirectorStart date: 2021-01-29

NCT03996369Phase 3Completed

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

StudydirectorStart date: 2020-09-15

NCT04162769Phase 2Completed

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

StudydirectorStart date: 2019-10-04

NCT04043455Phase 2Terminated

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Irritable Bowel Syndrome

StudydirectorStart date: 2019-07-24

NCT03945188Phase 3Completed

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

StudydirectorStart date: 2019-06-13

NCT03155932Phase 2Terminated

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

StudydirectorStart date: 2017-12-29

NCT03155945Phase 2Completed

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Abdominal PainCrohn's Disease

StudydirectorStart date: 2017-07-19

NCT03072953Phase 2Terminated

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Pyoderma Gangrenosum

StudydirectorStart date: 2017-06-07

NCT02536404Phase 2Completed

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

StudydirectorStart date: 2016-01-25

NCT02447302Phase 2Completed

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Ulcerative Colitis

StudydirectorStart date: 2015-10-15

Showing 10 of 11 trials

Research Network

Collaboration Network

1 collaborators·0 connections

Network Legend

KOL

Current Investigator

High-influence Collaborator

Collaborator

Click: view details

Double-click: go to profile

Drag: move node

Research Areas & Affiliations

Therapeutic Areas

Colitis, Ulcerative4 Irritable Bowel Syndrome2 Abdominal Pain1 Dermatitis, Atopic1 Crohn Disease1 Primary Biliary Cholangitis1 Primary Insomnia1 Pyoderma Gangrenosum1

Affiliations

Arena Pharmaceuticals

Similar Key Opinion Leaders

Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.

10 similar investigators found

Sabine Hazan, MD

ProgenaBiome

41 trials

Shared therapeutic areas:

Crohn DiseaseColitis, UlcerativeIrritable Bowel Syndrome

Similarity Score11%

emilie garrido pradalie

APHM

35 trials

Shared therapeutic areas:

Crohn DiseasePyoderma Gangrenosum

Similarity Score8%

Shivan Mehta, MD

University of Pennsylvania

16 trials

Shared therapeutic areas:

Crohn DiseaseColitis, Ulcerative

Similarity Score8%

Michael B Gill

Power Life Sciences Inc.

105 trials

Shared therapeutic areas:

Dermatitis, AtopicColitis, Ulcerative

Similarity Score8%

Faming Zhang, PhD

The Second Hospital of Nanjing Medical University

16 trials

Shared therapeutic areas:

Irritable Bowel SyndromeColitis, Ulcerative

Similarity Score8%

Danny de Looze, Professor

Gent University Hospital

1 trials

Shared therapeutic areas:

Crohn Disease

Similarity Score4%

Max Reinshagen, Professor

Kinikum Braunschweig

1 trials

Shared therapeutic areas:

Crohn Disease

Similarity Score4%

Javier Pérez Gisbert, MD

Hospital La Princesa, Madrid

1 trials

Shared therapeutic areas:

Crohn Disease

Similarity Score4%

Yoram Bouhnik, MD

Hôpital Beaujon, Clichy

1 trials

Shared therapeutic areas:

Crohn Disease

Similarity Score4%

Joaquín Hinojosa de Val, MD

Hospital de Manises, Valencia

1 trials

Shared therapeutic areas:

Crohn Disease

Similarity Score4%

Publications (0)

No publications found for this investigator.

Clinical Trials (11)

Showing 11 of 11 trials

NCT04655599Phase 1StudyDirector

Effect of Olorinab on Gastrointestinal Transit in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

Terminated

NCT03996369Phase 3StudyDirector

Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Completed

NCT04162769Phase 2StudyDirector

A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Completed

NCT04043455Phase 2StudyDirector

Olorinab in Irritable Bowel Syndrome With Predominant Constipation (IBS-C) and Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)

Irritable Bowel Syndrome

Terminated

NCT03945188Phase 3StudyDirector

Etrasimod Versus Placebo for the Treatment of Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Completed

NCT03155932Phase 2StudyDirector

Safety, Tolerability, and Efficacy of Etrasimod (APD334) in Participants With Primary Biliary Cholangitis

Primary Biliary Cholangitis

Terminated

NCT03155945Phase 2StudyDirector

Tolerability, Pharmacokinetics, and Efficacy of APD371 in Participants With Crohn's Disease Experiencing Abdominal Pain

Abdominal PainCrohn's Disease

Completed

NCT03072953Phase 2StudyDirector

Efficacy and Safety of APD334 in Patients With Pyoderma Gangrenosum

Pyoderma Gangrenosum

Terminated

NCT02536404Phase 2StudyDirector

Extension Study of APD334-003 in Patients With Moderately to Severely Active Ulcerative Colitis

Ulcerative Colitis

Completed

NCT02447302Phase 2StudyDirector

Safety and Efficacy of Etrasimod (APD334) in Patients With Ulcerative Colitis

Ulcerative Colitis

Completed

NCT00664664Phase 2StudyDirector

Subjective Study to Assess the Efficacy of APD125 in Patients With Sleep Maintenance Insomnia

Primary Insomnia

Completed

All 11 trials loaded